Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 3/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.50 |
| ▸ | BCL6 | P41182 | 17/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 6/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31444723 | 1.00 | DDB1 (0.50) | DDB1CRBNBCL6NCOR2ADRB3 | |
| SCHEMBL26754415 | 0.92 | BCL6 (0.44) | DDB1CRBNBCL6NCOR2ADRB3 | |
| SCHEMBL31444695 | 0.92 | BCL6 (0.44) | DDB1CRBNBCL6NCOR2ADRB3 | |
| SCHEMBL26752229 | 0.91 | BCL6 (0.44) | DDB1CRBNBCL6NCOR2ADRB3 | |
| SCHEMBL31444696 | 0.91 | BCL6 (0.44) | DDB1CRBNBCL6NCOR2ADRB3 | |
| SCHEMBL31444670 | 0.91 | DDB1 (0.45) | DDB1CRBNBCL6NCOR2ADRB3 | |
| SCHEMBL26752072 | 0.91 | DDB1 (0.45) | DDB1CRBNBCL6NCOR2ADRB3 | |
| SCHEMBL31702565 | 0.89 | DDB1 (0.50) | DDB1CRBNBCL6NCOR2 | |
| SCHEMBL26753026 | 0.89 | DDB1 (0.50) | DDB1CRBNBCL6NCOR2 | |
| SCHEMBL30661612 | 0.87 | DDB1 (0.51) | DDB1CRBNBCL6NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2023212147-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | CELGENE CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | BCL6, BCL6B, BCL3 | DDB1 280/4885CRBN 91/4885BCL6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.